Results 231 to 240 of about 275,402 (290)

Reduced colony‐stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression

British Journal of Haematology, Volume 209, Issue 3, Page 939-952, September 2026.
Summary Targeting the colony‐stimulating factor 1 receptor (CSF1R) to remove tumour‐associated macrophages is being explored as cancer therapy. This strategy may be relevant for chronic lymphocytic leukaemia (CLL), which strongly depends on support from myeloid cells.
Natascha Rosen, Guillermo Rodriguez‐Real, Alexander F. vom Stein, Luca D. Schreurs, Trong‐Hieu Nguyen, Viktoria Kohlhas, Thanh‐Tung Truong, Maximilian Koch, Sebastian Reinartz, Sumiya Iqbal, Shaista Ilyas, Sanjay Mathur, Nina Reinart, Phuong‐Hien Nguyen, Michael Hallek   +14 more
wiley   +1 more source

Mosunetuzumab Successfully Treated Rituximab-Refractory Lymphoma-Associated Protein-Losing Enteropathy With Concomitant Immune Thrombocytopenia in Follicular Lymphoma: A Case Report. [PDF]

EJHaem
Matsunaga T, Sahara N, Mizusawa M, Miura Y, Kobayashi S, Fujii T, Oono N.   +6 more
europepmc   +1 more source

BCL2-Negative Duodenal-Type Follicular Lymphoma Unmasked After <i>Helicobacter pylori</i> Eradication. [PDF]

ACG Case Rep J
Ganju N, Chirumamilla L, Nwachukwu CV, Adidam SR, Kibreab A.   +4 more
europepmc   +1 more source

Diffuse CD30‐Positive Cutaneous Infiltrate in a Clinically Suspected Hidradenitis Suppurativa Lesion: Histopathologic and Diagnostic Challenges

Journal of Cutaneous Pathology, Volume 53, Issue 9, Page 809-814, September 2026.
ABSTRACT Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting apocrine gland–bearing areas. We report a 38‐year‐old male with a lesion in the left axilla, initially clinically interpreted as HS and resistant to antibiotics.
R. Gervasi, G. L. Piazzetta, G. Soluri, C. Scigliano, C. Pelaia, V. Zuccalà, C. Gentile, N. Lobello, E. Allegra, E. Chiarella, N. Innaro   +10 more
wiley   +1 more source

CD20 Loss as a Mechanism of Resistance to Mosunetuzumab in Relapsed Follicular Lymphoma. [PDF]

Mediterr J Hematol Infect Dis
Canichella M, Fratoni S, Mazzone C, Di Rocco A, Abruzzese E.   +4 more
europepmc   +1 more source

The 2025 ATS/ERS update of the international multidisciplinary classification of the interstitial pneumonias: implications for the pathologist

Histopathology, Volume 89, Issue 3, Page 403-425, September 2026.
This review highlights changes relevant to pathologists in the updated multidisciplinary classification of interstitial pneumonias. Changes include expansion beyond idiopathic disease, subclassification as interstitial (fibrotic vs non‐fibrotic) and alveolar filling disorders, expansion to include additional patterns (e.g.
Andrew G Nicholson, Wendy A. Cooper, Aurelie Fabre, William Travis, Lida P. Hariri, Ayodeji Adegunsoye, Sara Piciucchi, Christopher J Ryerson   +7 more
wiley   +1 more source

Epcoritamab plus R² in follicular lymphoma: practice-changing efficacy meets unresolved toxicity trade-offs. [PDF]

Front Oncol
Ke Q, Zhou S.
europepmc   +1 more source

Cathepsin V (CTSV) Shapes the Epigenetic–Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker

International Journal of Urology, Volume 33, Issue 9, September 2026.
ABSTRACT Objective The aim of this study was to perform a comprehensive characterization of CTSV regulation in bladder cancer (BC) and its association with clinicopathological features, prognosis, and tumor stroma modulation using multi‐omics databases.
Wallax Augusto Silva Ferreira, Fabio Albuquerque Marchi, Glauco Akelinghton Freire Vitiello, Rolando André Rios Villacis, Ana Paula Drummond Rodrigues, Edivaldo Herculano Correa de Oliveira   +5 more
wiley   +1 more source

Chemotherapy-Sparing Strategies in Follicular Lymphoma: Emerging Targeted and Immune-Based Approaches. [PDF]

Eur J Haematol
Martino EA, Caserta S, Skafi M, Alvaro ME, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Vigna E, Morabito F, Gentile M.   +12 more
europepmc   +1 more source

Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1-3a follicular lymphoma. [PDF]

Front Immunol
Yu J, Sun C, Liu Q, Wang G, Wang J, Li L, Qiu L, Qian Z, Zhou S, Wang X, Zhang H.   +10 more
europepmc   +1 more source